---
title: "prechemo_breast"
slug: "prechemobreast"
date: "2023-10-06"
prefix: "prechemo_breast"
description: "ÁóÖ‰∫∫È¶ñÊ¨°‚úåÔ∏è Êé•Âèó‰π≥ÁôåÂåñÁôÇÁöÑ ‚Üí ÂøÖÂÅöÊ∏ÖÂñÆ"
enableToc: false
tags:
  - building
---

> [!info]
>
> üå± ‰æÜËá™: [[Chart template-of-breast cancer]]

# prechemo_breast

#### Education

- arranged Por-A implentation
- explained reason of adjuvant chemotherapy: cure and lower the risk of recurrence/metastasis.
  - most likely metastasis sites: liver, brain, lung, bone.
  - if metastasis, the 5-year survival rate is 26%
- explained chemotherapy schedule: `___` CAF or AC followed by T
  - OPD setting, no need for hospitalization
- explained potential chemotherapy toxicities:
  - common: fatigue, alopecia(reversible), nause/vomting, febrile neutropenia, opportunistic infection, infusion reaction (21% to 40% )
  - cyclophosphamide: bone marrow function compromised, hemorrhagic cystitis, secondary leukemia ( 0.5% ÂçÉÂàÜ‰πã‰∏Ä)
  - `___` doxorubicin: cardiotoxicity, life-time culmucation 450-500 mg/BSA ( `___` 240 `___` 300mg/BSA throught this course)
  - `___` fluorouracil: stomatitis or esophagopharyngitis, leukopenia, vomiting, diarrhea, frequent bowel movements, watery stools, gastrointestinal ulcer or bleeding, hand-foot syndrome
  - `___` docetaxel: stomatitis, persistent febrile neutropenia, cutaneous reactions, moderate neurosensory effects, secondary leukemia ( 0.5% )
- explained potential endorcine therapy toxicities:
  - AI: hot flashes, arthralgia, flushing, asthenia, edema, headache, osteoporosis and fractures, hypercholesterolemia, hepatic impairment
- explained potential ICI toxicities:
  - pembrolizumab: skin rash pneumonitis, colitis, hepatitis, hypophysitis, thyroid dysfunction, diabetes mellitus
- suggested high protein diet, not suggested additional supplement because it may confound the lab, which may lead to postponed the chemotherapy schedule.
- informed patient to avoid raw food, include fish, meat, vegetable
